A respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a strong immune response in a late-stage study involving four groups of immunocompromised adults aged 18 and older.

A single 120 microgram dose of the vaccine generated robust neutralizing antibodies against both RSV-A and RSV-B subtypes across all study groups. The vaccine was well-tolerated, with a safety profile consistent with previous studies.

The study included 203 adults across four groups: those with a type of lung cancer, end-stage kidney disease, autoimmune inflammatory disorder, and solid organ transplant recipients. These populations are at higher risk of developing severe RSV-associated disease due to their compromised immunity.

The vaccine manufacturer plans to submit the data to regulatory agencies for review.

Abrysvo is currently approved for adults aged 60 and older and for use in women during the middle of the third trimester of pregnancy to provide passive protection to infants.